Acta Clinica Belgica最新文献

{"title":"The eGFR dip after SGLT2 inhibition: when worsening kidney function does not mean kidney injury.","authors":"Charlotte Delrue, Marijn M Speeckaert","doi":"10.1080/17843286.2026.2739427","DOIUrl":"https://doi.org/10.1080/17843286.2026.2739427","url":null,"abstract":"","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-6"},"PeriodicalIF":0.9,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal AA amyloidosis associated with a TRAPS-like autoinflammatory phenotype and TNFRSF1A R92Q variant in adulthood.","authors":"Taha Enes Cetin, Serhat Haliloglu, Omer Faruk Akcay, Ozant Helvaci, Galip Guz","doi":"10.1080/17843286.2026.2700510","DOIUrl":"10.1080/17843286.2026.2700510","url":null,"abstract":"<p><strong>Background: </strong>Tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS) is a rare monogenic autoinflammatory disorder typically presenting with recurrent febrile attacks. However, adult-onset cases without classical inflammatory symptoms may remain unrecognized and can present with organ-dominant manifestations. AA amyloidosis represents a severe complication of chronic inflammation and may be the first clinical manifestation of an underlying autoinflammatory disease.</p><p><strong>Case presentation: </strong>We report a 48-year-old male with a history of vitiligo who presented with nephrotic syndrome. Renal biopsy confirmed AA amyloidosis. Despite progressive proteinuria and declining renal function, the absence of typical inflammatory symptoms delayed consideration of an autoinflammatory etiology. Empirical anti-inflammatory and biologic therapies, including IL-1 and IL-6 blockade, failed to control disease progression. The patient developed end-stage renal disease and died of septic shock. Post-mortem genetic analysis revealed a heterozygous TNFRSF1A (p.Arg121Gln) variant, supporting a possible atypical adult-onset TRAPS-like autoinflammatory phenotype.</p><p><strong>Conclusion: </strong>This case highlights the diagnostic challenge of TRAPS-like autoinflammatory phenotypes presenting in adulthood without classical inflammatory features, where AA amyloidosis may represent the first clinically apparent manifestation. Autoinflammatory diseases should be considered in adults with unexplained AA amyloidosis after exclusion of secondary causes. However, given the low penetrance and debated pathogenic significance of the TNFRSF1A R92Q variant, the observed genotype - phenotype association should be interpreted cautiously. Earlier recognition of a possible autoinflammatory etiology might offer a theoretical opportunity to limit progressive organ injury; however, whether this would alter outcomes in advanced presentations remains uncertain.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"461-466"},"PeriodicalIF":0.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer.","authors":"Margaux Van Damme, Ximena Elzo-Kraemer, An Deman, Christof Vulsteke, Amélie Dendooven, Liesbeth De Waele","doi":"10.1080/17843286.2026.2680287","DOIUrl":"10.1080/17843286.2026.2680287","url":null,"abstract":"<p><strong>Objectives: </strong>This article aims to highlight proteinuria and nephrotic syndrome as significant yet under-recognized adverse events of VEGF pathway inhibition by tyrosine kinase inhibitors (TKIs), illustrated in the treatment of radioiodine-refractory differentiated thyroid cancer.</p><p><strong>Methods: </strong>This report presents a case of recurring (nephrotic range) proteinuria in a patient with radioiodine-refractory differentiated thyroid cancer treated sequentially with lenvatinib, sorafenib and cabozantinib. In the discussion, an overview of the existing literature is provided through a PubMed search.</p><p><strong>Results: </strong>Reported incidence of proteinuria varies across VEGFR-targeted TKIs in clinical trials. However, direct comparisons between agents should be interpreted cautiously. The underlying pathophysiology is multifactorial, involving hypertension, endothelial injury, and direct podocyte damage, often resulting in focal segmental glomerulosclerosis, minimal change disease or non-thrombotic hyaline glomerular microangiopathy. Timely recognition and monitoring are essential, as early discontinuation or dose adjustment can lead to partial or full reversibility of renal damage. Switching to TKIs with a different nephrotoxic profile may be a feasible strategy to maintain oncological benefit while minimising renal risk. Nonetheless, given the limited evidence, this approach requires cautious implementation in selected cases.</p><p><strong>Conclusion: </strong>Proteinuria and nephrotic syndrome are an important class effect of VEGFR-directed TKIs. Regular monitoring, early detection, and timely dose adjustments or treatment switches are essential to minimize irreversible renal damage while maintaining oncological benefit.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"452-460"},"PeriodicalIF":0.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148194291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MEFV variants as phenotypic modifiers in ankylosing spondylitis: a genetic interaction analysis with HLA-B27.","authors":"Zeynep Irmak Kaya, Timuçin Kaşifoğlu","doi":"10.1080/17843286.2026.2691018","DOIUrl":"10.1080/17843286.2026.2691018","url":null,"abstract":"<p><strong>Background: </strong>MEFV mutations are prevalent in Mediterranean populations, yet their potential role in modulating ankylosing spondylitis (AS) remains unclear. We investigated whether MEFV variants act as susceptibility factors or modify disease phenotype via interaction with HLA-B27.</p><p><strong>Methods: </strong>In this cross-sectional study, 129 AS patients meeting the modified New York criteria, 51 rheumatoid arthritis controls, and 58 healthy controls were genotyped for 11 MEFV mutations using pyrosequencing. Radiographic severity was assessed using the Bath Ankylosing Spondylitis Radiographic Index (BASRI), scored by a blinded radiologist. Multivariate linear regression identified independent predictors of structural involvement, incorporating a multiplicative interaction term (HLA-B27×MEFV). Bonferroni correction was applied to post-hoc analyses.</p><p><strong>Results: </strong>MEFV carrier frequencies were similar across groups (29.5% in AS, 29.4% in RA, 22.4% in controls; <i>p</i> = 0.582), indicating no primary role in susceptibility. In multivariate analysis without interaction, disease duration (β = 0.379, <i>p</i> < 0.001) and male sex (β = 0.214, <i>p</i> = 0.017) independently predicted BASRI scores, whereas HLA-B27 and MEFV alone were not significant. Including the interaction term revealed a significant HLA-B27×MEFV effect (β = 0.243, <i>p</i> = 0.012), improving model fit (ΔR² = 0.034). Double-positive patients had higher BASRI scores than double-negatives (7.80 ± 4.15 vs. 4.80 ± 3.50; <i>p</i> = 0.008).      .</p><p><strong>Conclusion: </strong>MEFV variants do not increase AS susceptibility but are associated with greater structural involvement in HLA-B27-positive patients. This interaction identifies a high-risk genetic subgroup in endemic populations, highlighting implications for early identification and targeted monitoring.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"403-412"},"PeriodicalIF":0.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148275717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A decade of insulin pump therapy in a Belgian paediatric diabetes centre: longitudinal outcomes and evolving practices.","authors":"Anissa Messaaoui, Lucia Hajselova, Sylvie Tenoutasse","doi":"10.1080/17843286.2026.2682344","DOIUrl":"10.1080/17843286.2026.2682344","url":null,"abstract":"<p><strong>Aims: </strong>Continuous subcutaneous insulin infusion (CSII) is standard care in paediatric type 1 diabetes (T1D). This study evaluated 11-year trends in CSII adoption, device evolution, indications, discontinuation, and metabolic outcomes in a paediatric diabetes centre.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of children and adolescents with T1D followed from 2013 to 2024. Data included age at diagnosis and pump initiation, prior insulin regimen, device type, HbA1c, acute complications, and reasons for discontinuation or switching. Time to pump discontinuation was analysed using Cox regression.</p><p><strong>Results: </strong>CSII adoption increased to 41% of the centre's cohort by 2024. Devices evolved from 100% standalone pumps in 2013 to 54% hybrid closed-loop systems in 2024. At initiation, 36% started CSII within the first week after diagnosis, 58% transitioned from twice-daily injections, and 6% from multiple daily injections. Reasons for initiation included lifestyle considerations (51%), avoiding injections (21%), and suboptimal glycaemic control (13%). Mean HbA1c improved modestly over 5 years, with rare severe hypoglycaemia or ketoacidosis. CSII discontinuation occurred in 11%, mainly patient-driven, while 37% were physician-driven due to non-compliance. Older age at pump initiation was associated with discontinuation (HR 1.422, 95% CI 1.224-1.651; <i>p</i> < 0.001). Device switching occurred in 21%, mostly to access newer features.</p><p><strong>Conclusions: </strong>CSII adoption increased substantially over the study period, accompanied by a shift toward hybrid closed-loop systems and stable metabolic outcomes. Early initiation at diagnosis was feasible and safe. These real-world findings highlight the importance of education, adherence support, and multidisciplinary care in optimizing long-term paediatric CSII use.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"385-393"},"PeriodicalIF":0.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148147832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pneumococcal vaccination in Belgian adults: a practical translation of the 2025 Superior Health Council guidelines.","authors":"Steven Callens, Cato Dambre, Antoon De Schryver, Stefanie Desmet, Johan Flamaing, Michael Peeters, Laurence Vigneron, Yves Van Laethem","doi":"10.1080/17843286.2026.2671079","DOIUrl":"10.1080/17843286.2026.2671079","url":null,"abstract":"<p><strong>Background: </strong>Pneumococcal disease remains a significant burden in Belgian adults, with 2,120 cases of invasive pneumococcal disease (IPD) reported in 2024, the highest in a decade. Despite clear indications, vaccination uptake remains unacceptably low (13-24% in risk groups). Complex sequential vaccination schedules involving pneumococcal conjugate vaccines followed by the 23-valent polysaccharide vaccine (PPV23), combined with limited awareness among healthcare providers and the public, and incomplete reimbursement policies, have contributed to implementation barriers and poor adherence.</p><p><strong>Methods: </strong>This review provides a practice-oriented translation of the 2025 Superior Health Council of Belgium guidelines on adult pneumococcal vaccination. We analysed Belgian National Reference Centre 2024 serotype surveillance data to support age-stratified vaccine selection recommendations.</p><p><strong>Key recommendations: </strong>A single-dose conjugate vaccine approach now replaces all prior sequential regimens. Vaccine selection is age-stratified based on Belgian serotype epidemiology: PCV20 for adults 18-49 years with risk conditions (serotype 4 coverage critical); PCV20 or PCV21 for ages 50-84 years; and PCV21 preferred for adults ≥ 85 years (15% coverage advantage). PPV23 is eliminated from routine recommendations. Co-administration with influenza, RSV, and COVID-19 vaccines is supported, enabling maximal respiratory protection in a single visit.</p><p><strong>Conclusion: </strong>One conjugate vaccine dose, selected by age, provides maximal pneumococcal protection. The challenge is implementation to increase vaccination coverage: every clinical encounter with an at-risk adult is a vaccination opportunity.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"441-451"},"PeriodicalIF":0.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical late neurosyphilis presenting as status epilepticus: diagnostic and screening implications.","authors":"Sacha Pollet, Ludovic Ernon, Joris Meeuwissen, Hélène Boogaerts, Xavier Willaert, Els Oris, Tom Fivez, Ives Hubloue, Willem Boer","doi":"10.1080/17843286.2026.2739420","DOIUrl":"https://doi.org/10.1080/17843286.2026.2739420","url":null,"abstract":"<p><strong>Objectives: </strong>Neurosyphilis is a serious complication of poorly treated syphilis due to <i>Treponema pallidum</i> invasion of the central nervous system. Symptoms vary from silent infection to severe neurological deficits. Despite progress in diagnostics and treatment, the diagnosis is frequently missed because it is not considered, particularly in atypical presentations and in patients with no evident risk factor. .</p><p><strong>Methods: </strong>A 45-year-old man presented with confusion, speech difficulties, and left-sided weakness following subtle behavioral changes. In the emergency department, he had a witnessed focal-to-bilateral tonic-clonic seizure starting with head deviation to the left and tonic posturing of the left arm. Brain CT was normal, while MRI revealed right thalamic and bilateral temporal FLAIR hyperintensities with diffusion restriction in the thalamus. CSF showed mild pleocytosis (17 WBC/µL) and raised protein (67.6 mg/dL). Serum treponemal screening was positive with an RPR titre > 1:32. Neurosyphilis was confirmed by a reactive CSF non-treponemal test (RPR 1:2) in a patient with compatible clinical and CSF findings; the CSF TPHA titre was >1:10,240, which is supportive but not in itself a diagnostic criterion.Levetiracetam was started on admission and intravenous penicillin G on day 2, after the diagnosis was confirmed. Because EEG and MRI suggested possible focal status epilepticus, valproate and phenytoin were added. The patient developed respiratory failure needing mechanical ventilation and deep vein thrombosis. After extended ICU stay and rehabilitation, he recovered with mild residual critical illness myopathy and cognitive deficits.</p><p><strong>Conclusion: </strong>Neurosyphilis is not intrinsically difficult to diagnose, provided it is considered, including outside the classically recognised risk groups such as men who have sex with men.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-7"},"PeriodicalIF":0.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving psychosocial well being of older persons in Belgian nursing homes: key levers from policy to practice - a targeted review and expert consensus from the Belgian Superior Health Council.","authors":"Sylvie Gerard, Stefan Agrigoroaei, Marc Calmeyn, Katrin Gillis, Dominique Lamy, Anne Nobels, Ellen Van Leeuwen, Peter Van Bogaert, Linda Van Diermen, Tom Vermeulen, Mirko Petrovic","doi":"10.1080/17843286.2026.2737677","DOIUrl":"https://doi.org/10.1080/17843286.2026.2737677","url":null,"abstract":"<p><strong>Background: </strong>Belgian nursing homes increasingly care for residents with complex neurocognitive and psychiatric vulnerabilities, placing pressure on care systems structured around biomedical needs. Improving psychosocial well-being has therefore become a key quality of care challenge in long-term residential settings.</p><p><strong>Methods: </strong>This article presents a narrative synthesis based on the multidisciplinary advisory process conducted within the Belgian Superior Health Council (SHC). Findings from a targeted literature review were integrated with expert consensus to examine organizational and care-related factors influencing psychosocial well-being in nursing homes. Evidence was analysed according to determinants operating at three interrelated levels: clinical (micro), organizational (meso) and policy (macro).</p><p><strong>Results: </strong>Psychosocial well-being eresults from interacting mechanisms across multiple system levels. At the clinical level, person- and relationship-centred care, supported by non-pharmacological and personalized interventions, constitutes a key organizing principle. At the organizational level, staffing, leadership, training and multidisciplinary collaboration are critical enabling factors. At the policy level, the recognition of psychosocial and psychiatric complexity in financing, regulation and quality frameworks should facilitate implementation. Cross-cutting issues such as medication optimization and technological innovation, further highlight the need for coordinated action across levels. Overall, psychosocial well-being is influenced by determinants operating across multiple system levels and that coordinated multilevel strategies may offer a useful framework for addressing them.</p><p><strong>Conclusions: </strong>Improving psychosocial well-being in nursing homes requires a systemic and integrated approach linking policy , organizational conditions and clinical practices. A shift towards holistic, relationship-centred care is essential to support meaningful, dignified and connected lives for older persons.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-14"},"PeriodicalIF":0.9,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149023583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of nonsteroidal mineralocorticoid receptor antagonism on cardiorenal outcomes in diabetic kidney disease: a systematic review.","authors":"Maram Rabih Musa Rabih, Sara Elsayed Saeed Gharbawi, Samih Abdelmutalab Mohamed Abdalla, Amal Abdallah Suliman Said, Amel Babekir Abdelmajed Ahmed, Elkhansaa Ali Elsheikh Mohamed Elsamani, Alaa Abuagla Mahmoud Hussein","doi":"10.1080/17843286.2026.2731613","DOIUrl":"https://doi.org/10.1080/17843286.2026.2731613","url":null,"abstract":"<p><strong>Purpose: </strong>Diabetic kidney disease (DKD) is a major complication of type 2 diabetes and a leading cause of kidney failure and cardiovascular death. This review evaluated the cardiorenal effects and safety of nonsteroidal mineralocorticoid receptor antagonists (MRAs), particularly finerenone, in DKD.</p><p><strong>Methods: </strong>PubMed, Scopus, Embase, Web of Science, and ClinicalTrials.gov were searched through October 2024 for randomized controlled trials and prospective studies in adults with DKD. Two reviewers independently performed study selection, data extraction, and risk-of-bias assessment. Because eligible analyses were derived predominantly from the same two parent trials, quantitative pooling was avoided to prevent double-counting of participants.</p><p><strong>Results: </strong>Seven analyses from the FIDELITY programme (FIDELIO-DKD and FIGARO-DKD), representing 13,026 unique participants, were included. Finerenone reduced composite renal outcomes by 23% (HR 0.77, 95% CI 0.67-0.88) and cardiovascular outcomes by 14% (HR 0.86, 95% CI 0.78-0.95). Over approximately three years, absolute risk reductions were 1.6% for the kidney composite (5.5% vs 7.1%; NNT ≈60) and 1.7% for the cardiovascular composite (12.7% vs 14.4%). Benefits were generally consistent across subgroups and accompanied by reduced albuminuria and slower eGFR decline. Hyperkalemia was more frequent with finerenone (14.0% vs 6.9%) but rarely resulted in discontinuation (1.7% vs 0.6%).</p><p><strong>Conclusion: </strong>Finerenone provides meaningful cardiorenal protection in DKD with a manageable safety profile. However, evidence is largely limited to finerenone within a single trial programme; therefore, these findings should not be generalized to the entire nonsteroidal MRA class.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-13"},"PeriodicalIF":0.9,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148910475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral papilloedema secondary to central venous outflow obstruction in a haemodialysis patient: a case report.","authors":"Margot Smets, Britt Ceuleers, Rowena Vleut, Thomas Jardinet","doi":"10.1080/17843286.2026.2730185","DOIUrl":"https://doi.org/10.1080/17843286.2026.2730185","url":null,"abstract":"<p><p>Central venous stenosis is a common complication of vascular access in haemodialysis patients, often resulting in venous hypertension and inadequate dialysis. Intracranial hypertension is a rare but serious and potentially reversible manifestation of central venous outflow obstruction. We report the case of a haemodialysis patient who presented with right-sided periorbital oedema and bilateral papilloedema, a key sign of raised intracranial pressure. Extensive evaluation revealed central venous outflow obstruction due to an occlusion at the brachiocephalic vein junction and severe proximal right internal jugular vein stenosis, resulting in impaired cerebral venous drainage and intracranial hypertension. Percutaneous transluminal angioplasty led to complete resolution of the papilloedema. This case highlights the importance of early recognition of central venous-obstruction related intracranial hypertension in haemodialysis patients and initiating prompt intervention to prevent irreversible visual loss.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-7"},"PeriodicalIF":0.9,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148910416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}